ATCvet code: QI07AF
The product contains live B. bronchiseptica strain B-C2 and live canine parainfluenza virus strain Cornell. After intranasal vaccination, the product stimulates the development of active immunity against B. bronchiseptica and canine parainfluenza virus.
No data on the influence of maternal antibodies on the effect of vaccination with Nobivac KC are available. From literature, it is considered that this type of intranasal vaccine is able to induce an immune response without interference with maternally derived antibodies.
Data are available to show a reduction in shedding of B. bronchiseptica from 3 months to 1 year after vaccination.